Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer.

• DOI: 10.5144/0256-4947.2025.18
• Publication Date: 2025-02-11
• Authors: Nadiye Sever; Emil Yunusov; Abdüssamet Çelebi; Alper Yaşar; Nargiz Majıdova; Erkam Kocaaslan; Pınar Erel; Yeşim Ağyol; Ali Kaan Güren; Selver Işık; Rukiye Arıkan; Özlem Ercelep; Umut Kefeli; İbrahim Vedat Bay...; Murat Sarı
• Keywords: Peptidyl-Dipeptidase A

We aimed to explore the correlation between anti-hypertensive treatment and survival rates in patients with metastatic non-small cell lung cancer (mNSCLC). In this study, we analyzed antihypertensive 300 mNSCLC. Retrospective. Medical faculty hospital. investigated relationship who were diagnosed also examined histological type, performance status, gender, age type of medication used survival. Survival difference mNSCLC without treatment. Among receiving concomitant treatment, 107 (35.7%) prescribed angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB), 64 (21.3%) beta-blockers 36 (11%) calcium channel blockers. The study found that overall for all at 60 months 11.5% 7%, respectively. However, ACEi/ARB group had higher 18.1% 12% months, respectively, compared non-ACEi/ARB 8.7% 5% (P<.05). These results strongly suggest renin-angiotension system (RAS) hold great promise as potential adjunctive therapies due their significant inhibitory effects on proliferation, angiogenesis tumor progression. Retrospective non-randomized nature. Additionally, retrospective analysis did not allow verification duration regularity drug use, which made it infeasible examine dose-response relationships reliability.